PD-173074

N/A

Report date: 2025/12/17 10:59:04
NME

Base Information

Drug NamePD-173074
Drug Alias NamePD-173074PD-0173074
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 inhibitorsVascular endothelial growth factor receptor 2 inhibitors
TargetsFibroblast growth factor receptor 1Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsInflammationScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesFriedrich-Alexander University Erlangen-Nürnberg Fau
Inactive CompaniesPfizer Inc
Active IndicationsScleroderma, Systemic
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A